Claritas Rx

Overview

Claritas Rx is a SaaS-based data integration and analytics platform purpose-built for specialty and rare disease pharma brands. Its core value proposition is assembling fragmented, pre-dispense patient journey data — from specialty pharmacies, patient hubs, copay programs, field access teams, and payers — into a longitudinal, patient-level record that powers predictive AI models. The target buyer is the market access or patient services team at a biopharmaceutical manufacturer launching or managing a specialty or rare disease therapy.

Founded: 2011 by Mike Fitzgibbons, after six years at Genentech where he held roles spanning pricing strategy, managed care operations, and product marketing on the Avastin team. Previously an equity research analyst at Morgan Stanley. The company began generating commercial analytics in 2012 and has operated continuously since, making it one of the longer-tenured independent specialty analytics vendors.

Headquarters: South San Francisco, CA (611 Gateway Boulevard, Suite 201).

Ownership: In March 2021, Questa Capital — a venture growth equity firm focused on expansion-stage healthcare companies — made a “significant” growth equity investment, explicitly identifying itself as Claritas Rx’s first institutional investor. No investment amount disclosed. Questa managing partner Brad Sloan noted the firm had “tracked their innovation for years” before investing.

Scale: ~114 employees (grew ~27% YoY per Growjo), 5M+ patient-level data records, 20+ therapeutic areas served, four of the top 10 global pharma companies as clients. Named to the 2025 Inc. 5000 list of fastest-growing private companies, Inc.’s 2025 Best Workplaces list, and NASP Strategic Channel Partner of the Year.

Services & Capabilities

The commercial offering is organized under the Claritas Rx Ascend Platform, a cloud-hosted, API-first SaaS platform combining data aggregation, access analytics, predictive AI, case coordination, and competitive benchmarking.

Foundational Data Aggregation

Ingests and normalizes feeds from specialty pharmacies (SPs), patient hubs, copay/free-drug programs, call centers, field access teams, and payer sources. A proprietary Entity Mastering and Reconciliation engine reconciles patient, HCP, and payer identities across disparate systems, achieving >95% match accuracy. The resulting record provides “pre-dispense” visibility — covering data points that claims-based sources structurally cannot see (PA status, hub case activity, copay utilization, abandonment reason).

Patient Watchtower — Predictive Risk & Care Coordination

Launched at Asembia AXS25 in April 2025. Named PM360 2025 Best Innovation. Unites predictive risk scoring, case coordination workflow, and integrated omnichannel CRM:

AI/ML model accuracy claims:

• 80% accuracy predicting therapy discontinuation risk
• 80% accuracy predicting prior authorization denials
• 95% accuracy forecasting prescription abandonment

Validated outcomes: 20% fill rate improvement in patients with 30+ day time-to-fill; time-to-therapy reduced from 54 days to 19 days in a first-to-market launch supporting 50,000+ annual referrals; $30M+ in documented therapy value from a single deployment; 23,000 hours/year manual work reduction per customer.

Access Analytics & Performance Benchmarking

Launched October 2025. Real-time comparison of brand KPIs (fill rates, time-to-fill, abandonment, discontinuation) against competitors and therapeutic category analogs. The data is pre-dispense, enabling detection of competitive discontinuation events and prescriber engagement within days rather than months.

Consent Clearinghouse

Launched February 2026. Industry’s first centralized, standardized patient consent management solution. Consolidates patient permissions across partners in a single HIPAA-compliant environment. Early adopters reported 12-40% higher consent fill rates and 11% improvement in patient persistence.

Hub Integration Model

Claritas sits between pharma manufacturers and the hub/SP ecosystem as an analytics aggregator. Ingests data from hub vendors (CareMetx, AssistRx, Lash Group/Cencora, and others) and specialty pharmacy networks (including the Turning Point independent SP network via 2020 partnership). This aggregator-agnostic positioning provides manufacturers a unified view even when patients move between dispensing channels or hubs.

Competitive Position

vs. Hub Services Vendors (CareMetx, AssistRx, Lash Group): Complementary rather than competitive. Hub data feeds Claritas’s platform. However, as hubs build their own analytics and AI capabilities, competitive tension at the analytics layer may intensify.

vs. IQVIA / Symphony Health / Komodo Health: Large claims-based data providers. Structurally blind to pre-dispense specialty data. A specialty drug prescribed and abandoned before first fill generates no claim. Claritas’s pre-dispense coverage is genuine structural differentiation.

vs. IntegriChain: Market leader in GTN/channel data. Has patient journey analytics but primarily operational/financial. Claritas focuses on the clinical/commercial adjacency: patient access, fill rate, adherence. Overlapping customers but different questions.

vs. AssistRx’s Directive Analytics: Limited to data flowing through AssistRx’s own programs. Claritas’s aggregator-agnostic model serves a different buyer profile.

Sustainable moats: (1) Data network effects — more SP/hub partners = better model training. (2) Switching costs — once a brand builds workflows on Ascend, migrating requires re-aggregating all data pipelines. (3) Pre-dispense data exclusivity — no major competitor offers comparable cross-channel, pre-dispense patient-level view.

Recent Developments

February 2026 — Foundational Data Aggregation + Consent Clearinghouse Launch. Most comprehensive platform update to date. First centralized patient consent management in specialty pharma. 12-40% higher consent fill rates, 11% persistence improvement for early adopters.

October 2025 — HealthVerity Strategic Partnership. Links Claritas’s specialty pharmacy/hub/copay data with HealthVerity’s research-grade RWD (medical claims, pharmacy claims, EMR, lab). Positions Claritas as bridge between commercial analytics and HEOR/RWE — opening new buyer personas (medical affairs, HEOR, outcomes-based contracting teams).

October 2025 — AI-Powered Performance Benchmarking Launch. Real-time competitive KPI comparison with Market Alerts for patient switching detection.

August 2025 — Inc. 5000 Recognition. External validation of multi-year revenue acceleration.

April 2025 — Patient Watchtower Launch (Asembia AXS25). Flagship integrated platform merging predictive analytics, case coordination, and CRM. Earned PM360 2025 Best Innovations designation.

July 2025 — Time-to-Therapy Case Study. First-to-market therapy launch: 50,000+ annual referrals, average time-to-therapy cut from 54 days to 19 days.

Financial Profile

Source	Revenue Estimate
Growjo (2025)	~$16.5M ARR; ~$145K revenue/employee
ZoomInfo	~$25.4M

Questa Capital growth equity investment (March 2021) — first institutional funding. Questa typical check: $10-30M range (unconfirmed for this deal). Inc. 5000 membership confirms rapid revenue growth in the ~340-500% three-year range. With 20+ therapeutic areas and multi-product architecture, average contract value likely ranges from low-six-figures to mid-seven-figures.

Sources

• Claritas Rx About, Solutions, AI Thought Leadership, Questa Capital Investment PR, HealthVerity Partnership PR, Benchmarking Launch (Business Wire), Patient Watchtower PR, Inc. 5000, PM360 2025 Innovators, Consent Clearinghouse PR
• Perplexity Wave 2 Agent 17 enrichment (raw/research/08_claritas_rx.md)